• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h ventures limited has now launched the o2h therapeutics fund
Jul 9 2019
o2h-ventures

o2h Ventures Limited, an investment firm based in Cambridge, UK, has now launched “the o2h Therapeutics Fund” an early stage SEIS and/or EIS fund backing biotech therapeutic and related AI opportunities with plug-in capabilities in Cambridge, UK/India and a bridge to the USA.

The investment focus of the fund will be therapeutic drug opportunities or technologies that enable drug discovery with an emphasis on Artificial Intelligence (AI). The geographic scope shall be UK wide but will target the growing Cambridge biotech cluster which is now the global headquarters of AstraZeneca, and is home
to many biotech companies some of which have subsequently been snapped up by large pharmaceutical companies.

Large pharmaceutical companies have been closing down research centers globally for the last decade. This shift in focus of the large pharmaceutical companies has moved them from developing innovation in-house to acquiring innovation externally, forcing up the prices for the best science and providing earlier exit opportunities. The team at o2h have access to the most exciting scientific ideas through its live working relationships fostered over many years working as a discovery services company. This gives us far earlier access than competitors to the most promising companies.

Early stage companies often need more than just money, o2h Ventures has built a unique integrated model for early stage companies which includes the possibility of offering companies incubation in its o2h SciTech Park, in Cambridge, UK, and/or the option to jump-start their research activity from o2h Discovery in Ahmedabad, India.

o2h-ventures
(The Old Mill Warehouse – Incubation and co-working spaces and Hauxton House – o2h Ventures Global HQ.)

 

The fund is structured to be S/EIS compliant providing generous income, inheritance and capital gains tax breaks for UK tax payers.

Investors may download the investment memorandum at www.o2h.com/ventures

About o2h:

o2h seeds new ideas in science, technology and social enterprise. We work across boundaries and take acollaborative and shared approach to innovation, and therefore we co-invest, co-create and co-execute to bring these ideas to life.

o2h is co-located in Ahmedabad, India and in Cambridge UK and has 6 verticals coveringVentures, Co-work, Discovery Services, Therapeutics, Technology, and Community. Visit- www.o2h.com for more details.

Sunil Shah, CEO of o2h commented “We are really excited to launch the o2h ventures therapeutics fund. We see great deal flow through our hot network which is an accumulation of over 15 years of providing research services to this sector.”

The EIS benefits are a great way to invest in these fledgling businesses and access great British innovation in therapeutics whilst mitigating the risk through the tax benefits. We look forward to making our first investment in early 2019.

Contact:
Sunil Shah, Partner at o2h Ventures Limited
www.o2h.com/ventures
Mail- invest@o2h.com

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
recent press releases
  • o2h Ventures portfolio cos, raises funds o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science 28 February, 2023
  • o2h Ventures backed Small Pharma unveils positive phaseIIa results Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 January, 2023
  • Kuano wins Innovate UK grant o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 January, 2023
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • o2h Ventures deals pipeline, Knowledge-intensive EIS Fund closing on 5th April 2023
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)